Market analysis of Droperidol in the USA — overview of approvals, safety (QT prolongation), patent status, and strategic recommendations for potential reintroduction.

Etoricoxib, a selective COX-2 inhibitor by Merck, is widely approved outside the USA but remains unapproved domestically. Explore its global presence, patent landscape, clinical data, and regulatory challenges in the US market.

Aceclofenac is a widely used NSAID in Europe and China but remains unapproved in the USA. Explore its global approvals, patent landscape, clinical results, and strategies for US market entry.

Succinylcholine Chloride has been in the US market since 1952 as a key anesthetic agent. Explore its approvals, clinical results, patent barriers, and strategies for market entry and innovation.

Comprehensive market analysis of Sofosbuvir (Sovaldi) in the USA, covering FDA approvals, patents, exclusivity, clinical insights, and strategic recommendations for market entry.

Comprehensive analysis of Inclisiran in the USA, covering FDA approvals, patents, clinical results, regulatory exclusivity, and strategic insights for innovators and potential generic challengers.

Comprehensive market analysis of Dobutamine Hydrochloride in the USA, including FDA approvals, patent barriers, clinical data, regulatory risks, and strategic recommendations for generic manufacturers.

Explore the US market analysis of Lacosamide, including FDA approvals, patent landscape, clinical results, regulatory risks, and strategic recommendations for generic and innovator companies.

Discover the global market landscape of Amisulpride, including patent barriers, clinical insights, regulatory risks, and strategic opportunities in the US, China, and EU markets.

In March 2025, South Korea’s Ministry of Food and Drug Safety (MFDS) approved a total of 6 new FDCs across multiple therapeutic areas.

Suzetrigine received approval from the FDA on January 30, 2025, as a small-molecule pharmaceutical for the treatment of moderate to severe acute pain in adults.

The combination drug Meloxicam and Rizatriptan, received approval from the U.S. Food and Drug Administration (FDA) on January 30, 2025, for the treatment of migraine.